Search Within

Shanu Modi

  1. "Cancer Research"
Formats
  1. Meeting Abstract (50)
Groups
  1. Breast Medicine Service (50)
  2. Department of Medicine (50)
  3. Solid Tumor Oncology Division (50)
  4. GSK Faculty (24)
  5. Survivorship Research (23)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)

More Groups

People
  1. Clifford Hudis (18)
  2. Sarat Chandarlapaty (13)
  3. Sujata Patil (13)
  4. Larry Norton (12)
  5. Diana Lake (11)
  6. Gabriella D'Andrea-Carlino (10)

More People

Years
  1. 2022 (2)
  2. 2021 (5)
  3. 2020 (4)
  4. 2019 (5)
  5. 2018 (3)
  6. 2017 (2)

More Years

Publications
  1. Cancer Research (50)
Publishers
  1. American Association for Cancer Research (50)

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
    Meeting Abstract

    Forero-Torres, A.; Modi, S.; Specht, J.; Miller, K.; Weise, A.; Burris, H.; Liu, M.; Krop, I.; Pusztai, L.; Kostic, A.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Meeting Abstract

    Hyman, D. M.; Piha-Paul, S. A.; Rodón, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2- advanced breast cancer
    Meeting Abstract

    Bardia, A.; Modi, S.; Oliveira, M.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Nardi, L.; Zhang, V.; Bhansali, S. G.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
    Meeting Abstract

    Forero, A.; Burris, H. 3rd; Mita, M.; Specht, J.; Weise, A.; Liu, M. C.; Modi, S.; Pusztai, L.; Kostic, A.; Yang, J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
    Meeting Abstract

    Taldone, T.; Pillarsetty, N.; Dunphy, M. P. S.; Gerecitano, J. F.; Caldas-Lopes, E.; Beattie, B.; Peter, R. I.; Kang, Y. L.; Rodina, A.; Yan, P.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save